E
Elmar Jaeckel
Researcher at Hannover Medical School
Publications - 158
Citations - 4566
Elmar Jaeckel is an academic researcher from Hannover Medical School. The author has contributed to research in topics: Autoimmune hepatitis & Medicine. The author has an hindex of 29, co-authored 128 publications receiving 3903 citations. Previous affiliations of Elmar Jaeckel include Harvard University & Hochschule Hannover.
Papers
More filters
Journal ArticleDOI
Acute hepatitis C virus infection: to treat or not to treat?
Journal ArticleDOI
IDegLira is Efficacious Across Baseline HbA1C Categories in Subjects with Type 2 Diabetes Uncontrolled on SU, GLP-1RA or Insulin Glargine: Analyses from Completed Phase 3b Trials
Christopher Sorli,Stewart B. Harris,Esteban Jódar,Ildiko Lingvay,Jelena Vukmirica,Keval Chandarana,Jakob Langer,Elmar Jaeckel +7 more
Journal ArticleDOI
T cell receptor repertoires within liver allografts are different to those in the peripheral blood
Young-Seon Mederacke,Mikalai Nienen,Mikalai Nienen,Michael Jarek,Robert Geffers,Katharina Luise Hupa-Breier,Nina Babel,Nina Babel,Petra Reinke,Ingmar Mederacke,Florian W. R. Vondran,Danny Jonigk,Heiner Wedemeyer,Elmar Jaeckel +13 more
TL;DR: This is the first study comparing TCR repertoires between liver graft and blood in patients with NR, SCR and ACR and attributes specificity and function to a subgroup of intragraft T cell populations.
Journal ArticleDOI
Prolonged therapy of recurrent hepatitis B-infection after liver transplantation with nucleoside analogues
Elmar Jaeckel,Hans L. Tillmann,M Krueger,Hartmut Schmidt,Klaus H.W. Boeker,Christian Trautwein,Bjoern Nashan,I Bruns,M.P. Manns +8 more
Journal ArticleDOI
Naive tumour-specific CD4+ T cells were efficiently primed in acute lymphoblastic leukaemia.
Fatih Noyan,Thorsten Lieke,Richard Taubert,Maren Sievers,Janine Dywicki,Martin Hapke,Christine S. Falk,Michael P. Manns,Elmar Jaeckel,Matthias Hardtke-Wolenski +9 more
TL;DR: It is demonstrated that effective anti‐ALL immunity can be established by in vivo priming of CD4+ T cells that is sufficient to differentiate into effector cells.